Amgen (NASDAQ:AMGN) Upgraded by Barclays to Hold Rating

Amgen (NASDAQ:AMGN) was upgraded by equities research analysts at Barclays to a “hold” rating in a note issued to investors on Thursday,Zacks.com reports.

AMGN has been the topic of a number of other research reports. Rothschild & Co Redburn increased their price target on shares of Amgen from $180.00 to $200.00 and gave the stock a “sell” rating in a report on Wednesday. Wells Fargo & Company upped their target price on shares of Amgen from $325.00 to $375.00 and gave the stock an “equal weight” rating in a research report on Thursday. TD Cowen reissued a “buy” rating on shares of Amgen in a research note on Wednesday, February 4th. Deutsche Bank Aktiengesellschaft lifted their price target on Amgen from $285.00 to $295.00 and gave the stock a “hold” rating in a research note on Thursday, February 5th. Finally, Sanford C. Bernstein cut Amgen from an “outperform” rating to a “market perform” rating and set a $335.00 price objective for the company. in a report on Tuesday, January 20th. One investment analyst has rated the stock with a Strong Buy rating, fifteen have given a Buy rating, eleven have assigned a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat, Amgen presently has a consensus rating of “Moderate Buy” and an average target price of $351.76.

Amgen Stock Performance

Shares of AMGN opened at $374.75 on Thursday. The company has a market cap of $202.02 billion, a PE ratio of 26.34, a price-to-earnings-growth ratio of 3.80 and a beta of 0.46. The company has a current ratio of 1.14, a quick ratio of 0.90 and a debt-to-equity ratio of 5.78. The stock has a 50-day moving average price of $343.21 and a 200-day moving average price of $316.20. Amgen has a 12-month low of $261.43 and a 12-month high of $385.12.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings data on Tuesday, February 3rd. The medical research company reported $5.29 earnings per share for the quarter, topping the consensus estimate of $4.76 by $0.53. The company had revenue of $9.87 billion for the quarter, compared to analysts’ expectations of $9.46 billion. Amgen had a net margin of 20.98% and a return on equity of 148.37%. Amgen’s revenue for the quarter was up 8.6% compared to the same quarter last year. During the same period in the prior year, the business earned $5.31 earnings per share. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. As a group, equities analysts forecast that Amgen will post 20.62 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Amgen

Several institutional investors have recently bought and sold shares of the stock. Sequoia Financial Advisors LLC increased its stake in shares of Amgen by 2.3% during the third quarter. Sequoia Financial Advisors LLC now owns 160,646 shares of the medical research company’s stock valued at $45,334,000 after purchasing an additional 3,619 shares in the last quarter. Atlantic Union Bankshares Corp grew its stake in shares of Amgen by 165.0% in the 2nd quarter. Atlantic Union Bankshares Corp now owns 10,643 shares of the medical research company’s stock worth $2,972,000 after buying an additional 6,627 shares during the last quarter. Davis Capital Management purchased a new stake in shares of Amgen in the 3rd quarter worth approximately $1,841,000. D.A. Davidson & CO. increased its position in Amgen by 2.6% during the 3rd quarter. D.A. Davidson & CO. now owns 243,054 shares of the medical research company’s stock valued at $68,590,000 after buying an additional 6,222 shares in the last quarter. Finally, Global Wealth Management Investment Advisory Inc. raised its stake in Amgen by 56.2% during the third quarter. Global Wealth Management Investment Advisory Inc. now owns 13,056 shares of the medical research company’s stock valued at $3,684,000 after buying an additional 4,699 shares during the last quarter. 76.50% of the stock is currently owned by hedge funds and other institutional investors.

Key Headlines Impacting Amgen

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Rothschild & Co Redburn says Amgen’s stock price is expected to rise — a bullish analyst view that could support upside if reiterated or joined by others. Amgen (NASDAQ:AMGN) Stock Price Expected to Rise, Rothschild & Co Redburn Analyst Says
• Neutral Sentiment: Amgen priced $4.0 billion of senior unsecured notes across multiple maturities — this increases debt but provides liquidity; impact depends on use of proceeds (buybacks, M&A, refinancing). Investors should watch tenor and coupon details to assess financing cost and leverage effects. Amgen Prices $4 Billion Senior Unsecured Notes Offering
• Neutral Sentiment: Amgen has been a “trending” ticker on sites like Zacks and Yahoo — heightened attention can lift liquidity and volatility but is not a directional fundamental catalyst by itself. Amgen Inc. (AMGN) Is a Trending Stock: Facts to Know Before Betting on It
• Neutral Sentiment: “Here’s What the Street is Saying” roundups summarize mixed analyst commentary — useful for context but check individual firm views for conviction and PTs. Here’s What the Street is Saying About Amgen Inc. (AMGN)
• Neutral Sentiment: Short-interest data reported for mid-February appears to show 0 shares (NaN/incomplete) and a 0.0 days-to-cover metric — likely a reporting glitch; no reliable evidence here of a significant short squeeze or increase in bearish positioning.
• Negative Sentiment: Barclays initiated coverage with an “equal-weight” rating and a $350 price target, implying roughly a mid-single-digit downside from recent levels — this new coverage (and PT below the current price) is a near-term headwind for sentiment. Barclays initiates coverage of Amgen (AMGN) with equal-weight recommendation

Amgen Company Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.